Providers

Laxmi Patel urges hospitals to embed financial screening and simplify payment options to prepare for rising levels of uninsured patients from Medicaid changes.

Teamwork between primary care providers and oncologists helps patients get needed care and achieve better results, according to Mark Fendrick, MD, at the Patient-Centered Oncology Care (PCOC) conference.

Kathy Oubre, MS, discusses opportunities for community cancer centers to expand service lines without sacrificing care quality.

Panelists discussed the ingredients of successful handoffs at the time of cancer diagnosis and ways to collaborate as screening capabilities evolve.

Oncology utilization management often frustrates patients and payers, but collaboration and artificial intelligence can streamline processes and improve care quality, according to Vishnukamal Golla, MD, MPH.

Researchers found that even smaller open artificial intelligence (AI) models outperformed clinicians, supporting automation of International Classification of Disease (ICD) coding.

From proactive recruitment to academic-community partnerships, Hope Krebill highlights ways to improve clinical trial participation.

Oral nicotinamide reduced the risk of new skin cancers—especially squamous cell carcinoma—by up to 54% when started after a first diagnosis.

These patients had a higher spleen-to-liver stiffness ratio than those with alcohol-related liver disease, warranting a closer look at testing.

Patients with progressive pulmonary fibrosis had longer survival with antifibrotic therapy, but only if they met a key criteria.

Laxmi Patel outlines how Medicaid reforms could raise bad debt, urging providers to strengthen financial counseling, assistance, and price transparency.

Laxmi Patel explains how Medicaid reforms could increase uncompensated care and the burden on hospitals, and how technology can help automate workflows.

Female patients with chronic spontaneous urticaria (CSU) face greater disease severity and burdens, particularly in midlife, a study found.

Positive topline data from the phase 3 BRUIN CLL-313 showed pirtobrutinib's efficacy in the frontline setting.

This case highlights the diagnostic complexity and clinical management challenges of dual hematologic malignancies.

Research shows more than a third of patients with rheumatoid arthritis met criteria for frailty, with prefrailty and robust groups closely following.

Patients with acute exacerbations of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis face steep odds and benefit from palliative care.

Gary Falcetano, PA-C, AE-C, discussed the correlation between climate change and allergy health risks.

Ruxolitinib cream 15 mg/g provided rapid, meaningful repigmentation and improved quality of life for adults with nonsegmental vitiligo.

This article presents a systematic review of US health care disparities in physician specialist access across rheumatology, dermatology, and gastroenterology and a call to action.

The Rural Health Transformation Program invests $50 billion to enhance health care access and quality in rural America.

Drug interactions with ibrutinib may not shorten survival when managed carefully, though the significant increase in infection-related hospitalizations tied to CYP3A inhibitors signals an urgent need for closer monitoring, dose adjustment, and proactive infection prevention strategies.

Patients who underwent neoadjuvant radiotherapy for soft tissue sarcoma (STS) spent longer in the hospital and were more likely to have wound complications.

This commentary calls for health care systems to deliver equitable care for people living with obesity by addressing weight bias and updating standards in obesity care.

Underdosing, poor spleen response, and transfusion dependence drive inferior survival outcomes in intermediate-1 myelofibrosis.

Mepolizumab showed significant real-world improvements in asthma outcomes, reducing exacerbations and corticosteroid use in severe eosinophilic asthma.

By 2040, advanced metabolic dysfunction–associated steatohepatitis (MASH) is projected to rise by at least 20% in the 9 countries assessed.

Among survey respondents, approximately 80% reported experiencing stigma, including feelings of embarrassment, negative judgment, or being treated differently, because of their condition.

Among patients with hematologic malignancies who were diagnosed with COVID-19, about one-quarter experienced critical illness, and most of those patients died.

As the prevalence of both chronic kidney disease (CKD) and heart failure (HF) increases, therapies targeting shared pathways are one of the most promising strategies to alter the trajectory of these diseases.